Abstract 345P
Background
While induction with cytarabine containing immuno-chemotherapy is recommended for fit patients (pts) with newly diagnosed mantle cell lymphoma (MCL), the choice of accompanying platinum agent is less clear. Substitution to carboplatin simplifies chemotherapy administration and reduces nephrotoxicity. We aimed to assess the impact of up to 6 cycles of alternating RCHOP/RDHAC (carboplatin) as induction for transplant-eligible pts with MCL prior to BEAM autologous stem cell transplant (ASCT).
Methods
Single centre retrospective cohort study [2008-2023] of pts who commenced RCHOP/RDHAC for MCL. Descriptive statistics, Kaplan-Meier survival analysis, impact of baseline variables tested, and nephrotoxicity graded by CTCAE v5.
Results
Of 36 pts identified, 34 completed intended therapy. Median age was 63 yrs (range 37-76), 32 males (89%), stage 4=28 (78%), MIPI low 33%/int 47%/high 19%, aggressive morphology=19%, p53=90% (9/10) and high Ki67=63% (15/24). Mean induction relative dose intensity was 99% (SD 5%). Autograft was performed in 26 pts; insufficient stem cell collection in 1 patient. Response was evaluable by PET/CT prior to autograft in 31 pts; not assessed in 5 pts: 25 complete response, 5 partial response and 1 progressive disease (ORR 97%). By Jun 2023, with median (m) follow-up of 85 mo: 16 pts died, 12 relapsed; mPFS 90 mo and mOS 112 mo; mOS following relapse/progression 16 mo despite bruton tyrosine kinase inhibitor use in 7 pts (54%). Nephrotoxicity with induction was uncommon (Table); 1 pt required dialysis in setting of organ failure associated with sepsis. Median admission duration per pt for induction therapy was 5 days (IQR, 0-9.5). Table: 345P
Table: 345P Adverse events
No. pts | |
Creatinine increase- Grade 1/2- Grade 3/4 | 8 (22%)1 (3%) |
Acute kidney injuryˆ- Grade 3- Grade 4 | 1 (3%)1 (3%) |
Febrile neutropenia | 9 (25%) |
Transplant-related mortality* | 3 (8%) |
ˆincludes 1 pt with sepsis during stem cell mobilization with RDHAC; 1 pt with acute on chronic renal impairment with RCHOP*includes 1 pt with sepsis during stem cell mobilization with RDHAC
Conclusions
This retrospective analysis is one of the largest cohorts of RCHOP/RDHAC reported in MCL. Low rates of clinically relevant nephrotoxicity with comparable long-term outcomes highlight carboplatin substitution as an option in selected pts. Survival after relapse remains poor.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
183P - Final analysis of phase II clinical study evaluating the safety and effectiveness of neoadjuvant S-1 + oxaliplatin combination therapy for older patients with locally advanced gastric cancer
Presenter: Eiji Oki
Session: Poster Display
Resources:
Abstract
184P - Neutropenia as a predictive and prognostic factor in nanoliposomal-irinotecan/fluorouracil/leucovorin therapy for pancreatic cancer: Findings from the NAPOLEON-2 study (NN-2301)
Presenter: Yuki Sonoda
Session: Poster Display
Resources:
Abstract
185P - Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
186P - Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial
Presenter: Xiaoting Ma
Session: Poster Display
Resources:
Abstract
187P - Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)
Presenter: Yongguang Wei
Session: Poster Display
Resources:
Abstract
188P - Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Margherita Rimini
Session: Poster Display
Resources:
Abstract
189P - Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Shun Yamamoto
Session: Poster Display
Resources:
Abstract
190P - Perioperative camrelizumab combined with chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, single-center, phase II clinical trial
Presenter: Jiaxing He
Session: Poster Display
Resources:
Abstract
191P - Predictive value of CXCR6 expression in gastric cancer survival and immune modulation
Presenter: Song-Hee han
Session: Poster Display
Resources:
Abstract
192P - Antiangiogenesis-related adverse events (ARAE) to predict efficacy in patients with advanced gastric cancer (AGC) treated with apatinib + chemotherapy: Results from two prospective studies
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract